L

Lipella Pharmaceuticals Inc
NASDAQ:LIPO

Watchlist Manager
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Watchlist
Price: 0.2012 USD Market Closed
Market Cap: 929.5k USD

Lipella Pharmaceuticals Inc
Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Lipella Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
L
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Cash Equivalents
$2.2m
CAGR 3-Years
16%
CAGR 5-Years
143%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$5.6B
CAGR 3-Years
-22%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$9.4B
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$6.3B
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
24%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.5B
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Lipella Pharmaceuticals Inc
Glance View

Market Cap
929.5k USD
Industry
Biotechnology

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.

LIPO Intrinsic Value
0.8566 USD
Undervaluation 77%
Intrinsic Value
Price
L

See Also

What is Lipella Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
2.2m USD

Based on the financial report for Dec 31, 2024, Lipella Pharmaceuticals Inc's Cash Equivalents amounts to 2.2m USD.

What is Lipella Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
143%

Over the last year, the Cash Equivalents growth was -34%. The average annual Cash Equivalents growth rates for Lipella Pharmaceuticals Inc have been 16% over the past three years , 143% over the past five years .

Back to Top